GAO Criticizes Genomic Tools for Adding Cost but Not Productivity to Drug Development | GenomeWeb
NEW YORK (GenomeWeb News) — The Government Accountability Office, the federal watchdog for government spending, said genomic technologies have reduced drug-development productivity while adding to R&D costs in recent years.
 
In a report it issued last month, “New Drug Development: Science, Business and Intellectual Property Issues Cited as Hampering Drug Development Efforts,” the GAO criticizes the slow pace and high costs of drug development and in one section blames genomic technologies.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.